Recent studies have centered on the convergence of GLP|GIP|GCGR agonist therapies and dopamine neurotransmission. While GLP activators are widely employed for addressing type 2 diabetes mellitus, their unexpected effects on motivation circuits, specifically governed by dopaminergic systems, are receiving significant focus. This report details a sum